Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the
treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.